| 'Therapeutic drug monitoring'van tyrosinekinaseremmers: precisiegeneeskunde nog doeltreffender R Ter Heine, ADR Huitema, RHJ Mathijssen, EM van Maarseveen, ... Nederlands Tijdschrift voor Oncologie 12 (7), 267-276, 2015 | 3 | 2015 |
| 42P Development of an online tool for the management of drug-drug interactions with the ROS1/TRK tyrosine kinase inhibitor repotrectinib D Burger, LJ Nijboer, M van den Heuvel, J Leentjens, AJ van der Wekken, ... ESMO Open 9, 2024 | | 2024 |
| 769P Pharmacokinetic boosting of olaparib: An open-label, prospective, cross-over study J Overbeek, N Guchelaar, MIM Ali, PB Ottevanger, H Bloemendal, ... Annals of Oncology 34, S522, 2023 | | 2023 |
| 858: A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: A Proof-of-Concept Study S Hartman, J Swaving, S Van Beek, B Van Groen, M De Hoop, ... Critical Care Medicine 49 (1), 426, 2021 | | 2021 |
| A 25% higher vancomycin maintenance dose is required in neutropenic hematologic patients. D Bury, R ter Heine, EMW van de Garde, RJ Grouls, MJ Deenen Nederlands Platform voor Farmaceutisch Onderzoek, 2017 | | 2017 |
| A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration‐resistant metastatic prostate cancer GE Benoist, MJ van der Doelen, R Ter Heine, NP van Erp, N Mehra British Journal of Clinical Pharmacology 84 (5), 1064-1067, 2018 | 5 | 2018 |
| A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled … R Ter Heine, H Rosing, JH Beijnen, ADR Huitema Clinical chemistry and laboratory medicine 48 (8), 1153-1155, 2010 | 7 | 2010 |
| A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions N de Rouw, S Visser, SLW Koolen, JGJV Aerts, MM van den Heuvel, ... Cancer Chemotherapy and Pharmacology 85, 231-235, 2020 | 5 | 2020 |
| A mechanism-based population pharmacokinetic analysis assessing the feasibility of efavirenz dose reduction to 400 mg in pregnant women S Schalkwijk, R Ter Heine, AC Colbers, ADR Huitema, P Denti, ... Clinical Pharmacokinetics 57 (11), 1421-1433, 2018 | 9 | 2018 |
| A meta-analysis of protein binding of flucloxacillin in healthy volunteers and hospitalized patients E Wallenburg, RJM Brüggemann, JA Roberts, NGL Jager, M Ulldemolins, ... Clinical Microbiology and Infection 28 (3), 446. e1-446. e7, 2022 | 14 | 2022 |
| A model-informed method for the purpose of precision dosing of isoniazid in pulmonary tuberculosis SW van Beek, R Ter Heine, JWC Alffenaar, C Magis-Escurra, ... Clinical Pharmacokinetics 60, 943-953, 2021 | 11 | 2021 |
| A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis (February, 10.1007/s40262-020-00971-2, 2021) SW van Beek, R ter Heine, JWC Alffenaar, C Magis-Escurra, ... CLINICAL PHARMACOKINETICS 60 (7), 955-955, 2021 | | 2021 |
| A multicomponent intervention program to Prevent and Reduce AgItation and phySical rEstraint use in the ICU (PRAISE): study protocol for a multicenter, stepped-wedge, cluster … RWJ Kooken, B Tilburgs, R Ter Heine, B Ramakers, M van den Boogaard Trials 24 (1), 800, 2023 | 1 | 2023 |
| A new framework to implement model-informed dosing in clinical guidelines: piperacillin and amikacin as proof of concept SJF Hartman, JGE Swaving, SW Van Beek, BD Van Groen, M De Hoop, ... Frontiers in Pharmacology 11, 592204, 2020 | 11 | 2020 |
| A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations R Heine, HJ Scherpbier, KML Crommentuyn, V Bekker, JH Beijnen, ... Antiviral therapy 13 (6), 779-787, 2008 | 78 | 2008 |
| A pharmacokinetic model for the influence of intestinal and hepatic CYP3A4 expression on the in‐vivo disposition of lopinavir and its modulation by ritonavir R ter Heine, RA van Waterschoot, RJ Keizer, JH Beijnen, AH Schinkel, ... Bioanalysis, metabolism & clinical pharmacology of antiretroviral drugs, 155, 2009 | | 2009 |
| A pharmacological rationale for improved everolimus dosing in oncology and transplant patients R Ter Heine, NP van Erp, HJ Guchelaar, JW de Fijter, MEJ Reinders, ... British Journal of Clinical Pharmacology 84 (7), 1575-1586, 2018 | 18 | 2018 |
| A randomized study of intensified antiretroviral treatment monitoring versus standard-of-care for prevention of drug resistance and antiretroviral treatment switch LE Hermans, R Ter Heine, R Schuurman, HA Tempelman, DM Burger, ... AIDS 36 (14), 1959-1968, 2022 | 3 | 2022 |
| A semi-physiological population model to quantify the effect of hematocrit on everolimus pharmacokinetics and pharmacodynamics in cancer patients NP van Erp, CM van Herpen, D de Wit, A Willemsen, DM Burger, ... Clinical Pharmacokinetics 55, 1447-1456, 2016 | 23 | 2016 |
| A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients MR Heerma van Voss, J Notohardjo, J van Dodewaard-de Jong, ... Cancer Chemotherapy and Pharmacology, 1-5, 2024 | | 2024 |
Roger Bruggemann在 radboudumc.nl 的电子邮件经过验证
